Andere Sprachen Camurus AB

Aktien

A2ABG7

SE0007692850

CAMX

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:47 19.04.2024			% 5 Tage	% 1. Jan.
485 ^SEK	+2,41 %		-4,81 %	-9,85 %

02.04.	Camurus AB (Publ) kündigt Rücktritte aus dem Verwaltungsrat an	CI
05.03.	Camurus' neuer Medikamentenantrag für Akromegalie-Behandlung von der US FDA akzeptiert	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17.04.
Notice of annual general meeting 2024 in Camurus (publ)	02.04.
Camurus AB Announces Board Resignations	02.04.
Camurus Annual Report for 2023	28.03.
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05.03.
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	05.03.
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05.03.
OPINIONES DE LOS ANALISTAS DEL DÍA : Acciona, Amadeus, Acs, Endesa, Ferrari, Heineken, Iberdrola, Prosegur, Salvatore Ferragamo...	04.03.
AVIS D'ANALYSTES DU JOUR : Sanofi, Stellantis, Orange, STMicroelectronics, OVH, UCB, Valeo...	04.03.
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest	15.02.
Camurus' Full Year Report 2023	15.02.
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.02.
Camurus AB Provides Earnings Guidance for the Full Year 2024	15.02.
Camurus appoints Behshad Sheldon as President of Camurus Inc.	13.02.
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	13.02.
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease	08.02.
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08.02.
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders	18.01.
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million	18.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Camurus AB

Aktien

A2ABG7

SE0007692850

CAMX

Andere Sprachen

Filter